Anti-ErbB-2 mAb therapy requires type I and II interferons and synergizes with anti-PD-1 or anti-CD137 mAb therapy

Proceedings of the National Academy of Sciences of the United States of America

Volumn 108, Issue 17, 2011, Pages 7142-7147

  Stagg, John ^a,e   Loi, Sherene ^b   Divisekera, Upulie ^a   Ngiow, Shin Foong ^a,c   Duret, Helene ^a   Yagita, Hideo ^d   Teng, Michele W ^a,c   Smyth, Mark J ^a,c  

^a PETER MACCALLUM CANCER CENTRE   (Australia)

^b JULES BORDET INSTITUTE   (Belgium)

^c UNIVERSITY OF MELBOURNE   (Australia)

^d JUNTENDO UNIVERSITY SCHOOL OF MEDICINE   (Japan)

^e CENTRE HOSPITALIER DE L UNIVERSITÉ DE MONTRÉAL   (Canada)

Author keywords

Adaptive; Innate; Natural killer cell; Tumor immunology

Indexed keywords

CD137 ANTIGEN; CD137 MONOCLONAL ANTIBODY; EPIDERMAL GROWTH FACTOR RECEPTOR 2 MONOCLONAL ANTIBODY; EPIDERMAL GROWTH FACTOR RECEPTOR ANTIBODY; FAS LIGAND; GAMMA INTERFERON; INTERFERON; INTERLEUKIN 1 RECEPTOR; INTERLEUKIN 17 RECEPTOR; MONOCLONAL ANTIBODY; MYELOID DIFFERENTIATION FACTOR 88; PERFORIN; PROGRAMMED DEATH 1 MONOCLONAL ANTIBODY; PROGRAMMED DEATH 1 RECEPTOR; TRASTUZUMAB; UNCLASSIFIED DRUG;

ADAPTIVE IMMUNITY; ADOPTIVE TRANSFER; ANIMAL CELL; ANIMAL EXPERIMENT; ANIMAL MODEL; ANTIBODY RESPONSE; ARTICLE; BREAST CANCER; CD8+ T LYMPHOCYTE; CONTROLLED STUDY; CYTOKINE PRODUCTION; CYTOKINE RELEASE; CYTOPATHOGENIC EFFECT; DRUG MECHANISM; FEMALE; IMMUNE RESPONSE; IMMUNOSTIMULATION; IMMUNOTHERAPY; INNATE IMMUNITY; LYMPHOCYTE MEDIATED CELLULAR CYTOTOXICITY; MOUSE; NONHUMAN; PRIORITY JOURNAL; SIGNAL TRANSDUCTION; T LYMPHOCYTE SUBPOPULATION; TRANSGENIC MOUSE;

MOUSE MAMMARY TUMOR VIRUS; MUS; MUS MUSCULUS;

EID: 79955570584     PISSN: 00278424     EISSN: 10916490     Source Type: Journal    
DOI: 10.1073/pnas.1016569108     Document Type: Article

References (34)

1. Hudis CA (2007) Trastuzumab - mechanism of action and use in clinical practice. N Engl J Med 357:39-51.
2. Spector NL, Blackwell KL (2009) Understanding the mechanisms behind trastuzumab therapy for human epidermal growth factor receptor 2-positive breast cancer. J Clin Oncol 27:5838-5847.
3. Untch M, et al. (2010) Neoadjuvant treatment with trastuzumab in HER2-positive breast cancer: Results from the GeparQuattro study. J Clin Oncol 28:2024-2031.
4. Clynes RA, Towers TL, Presta LG, Ravetch JV (2000) Inhibitory Fc receptors modulate in vivo cytoxicity against tumor targets. Nat Med 6:443-446. (Pubitemid 30208162)
5. Musolino A, et al. (2008) Immunoglobulin G fragment C receptor polymorphisms and clinical efficacy of trastuzumab-based therapy in patients with HER-2/neu-positive metastatic breast cancer. J Clin Oncol 26:1789-1796.
6. Varchetta S, et al. (2007) Elements related to heterogeneity of antibody-dependent cell cytotoxicity in patients under trastuzumab therapy for primary operable breast cancer overexpressing Her2. Cancer Res 67:11991-11999.
7. Arnould L, et al. (2006) Trastuzumab-based treatment of HER2-positive breast cancer: An antibody-dependent cellular cytotoxicity mechanism? Br J Cancer 94:259-267.
8. Gennari R, et al. (2004) Pilot study of the mechanism of action of preoperative trastuzumab in patients with primary operable breast tumors overexpressing HER2. Clin Cancer Res 10:5650-5655. (Pubitemid 39180938)
9. Junttila TT, et al. (2010) Superior in vivo efficacy of afucosylated trastuzumab in the treatment of HER2-amplified breast cancer. Cancer Res 70:4481-4489.
10. Park S, et al. (2010) The therapeutic effect of anti-HER2/neu antibody depends on both innate and adaptive immunity. Cancer Cell 18:160-170.
11. Ghiringhelli F, et al. (2009) Activation of the NLRP3 inflammasome in dendritic cells induces IL-1beta-dependent adaptive immunity against tumors. Nat Med 15:1170-1178.
12. Zhang H, et al. (1999) Shared antigenic epitopes and pathobiological functions of anti-p185(her2/neu) monoclonal antibodies. Exp Mol Pathol 67:15-25. (Pubitemid 29449450)
13. Stagg J, et al. (2008) Antibodies targeted to TRAIL receptor-2 and ErbB-2 synergize in vivo and induce an antitumor immune response. Proc Natl Acad Sci USA 105: 16254-16259.
14. Di Carlo E, et al. (1999) Analysis of mammary carcinoma onset and progression in HER-2/neu oncogene transgenic mice reveals a lobular origin. Lab Invest 79:1261-1269. (Pubitemid 29489450)
15. Koebel CM, et al. (2007) Adaptive immunity maintains occult cancer in an equilibrium state. Nature 450:903-907. (Pubitemid 350231320)
16. Swann JB, et al. (2007) Type I IFN contributes to NK cell homeostasis, activation, and antitumor function. J Immunol 178:7540-7549. (Pubitemid 46898022)
17. Takeda K, et al. (2001) Involvement of tumor necrosis factor-related apoptosisinducing ligand in surveillance of tumor metastasis by liver natural killer cells. Nat Med 7:94-100. (Pubitemid 32095647)
18. van Dommelen SL, et al. (2006) Perforin and granzymes have distinct roles in defensive immunity and immunopathology. Immunity 25:835-848. (Pubitemid 46107286)
19. Swann JB, et al. (2008) Demonstration of inflammation-induced cancer and cancer immunoediting during primary tumorigenesis. Proc Natl Acad Sci USA 105:652-656. (Pubitemid 351171763)
20. Esteva FJ, et al. (2007) CD40 signaling predicts response to preoperative trastuzumab and concomitant paclitaxel followed by 5-fluorouracil, epirubicin, and cyclophosphamide in HER-2-overexpressing breast cancer. Breast Cancer Res 9:R87.
21. Brahmer JR, et al. (2010) Phase I study of single-agent anti-programmed death-1 (MDX-1106) in refractory solid tumors: Safety, clinical activity, pharmacodynamics, and immunologic correlates. J Clin Oncol 28:3167-3175.
22. Westwood JA, et al. (2009) Toll-like receptor triggering and T-cell costimulation induce potent antitumor immunity in mice. Clin Cancer Res 15:7624-7633.
23. zum Büschenfelde CM, Hermann C, Schmidt B, Peschel C, Bernhard H (2002) Antihuman epidermal growth factor receptor 2 (HER2) monoclonal antibody trastuzumab enhances cytolytic activity of class I-restricted HER2-specific T lymphocytes against HER2-overexpressing tumor cells. Cancer Res 62:2244-2247.
24. Taylor C, et al. (2007) Augmented HER-2 specific immunity during treatment with trastuzumab and chemotherapy. Clin Cancer Res 13:5133-5143. (Pubitemid 47502081)
25. Mittendorf EA, Storrer CE, Shriver CD, Ponniah S, Peoples GE (2006) Investigating the combination of trastuzumab and HER2/neu peptide vaccines for the treatment of breast cancer. Ann Surg Oncol 13:1085-1098. (Pubitemid 44337968)
26. Benavides LC, et al. (2009) The impact of HER2/neu expression level on response to the E75 vaccine: From U.S. Military Cancer Institute Clinical Trials Group Study I-01 and I-02. Clin Cancer Res 15:2895-2904.
27. Kaufmann M, et al. (2003) International expert panel on the use of primary (preoperative) systemic treatment of operable breast cancer: Review and recommendations. J Clin Oncol 21:2600-2608. (Pubitemid 46606344)
28. Burstein HJ, Winer EP (2009) Refining therapy for human epidermal growth factor receptor 2-positive breast cancer: T stands for trastuzumab, tumor size, and treatment strategy. J Clin Oncol 27:5671-5673.
29. Li B, et al. (2009) Anti-programmed death-1 synergizes with granulocyte macrophage colony-stimulating factor-secreting tumor cell immunotherapy providing therapeutic benefit to mice with established tumors. Clin Cancer Res 15:1623-1634.
30. Berger R, et al. (2008) Phase I safety and pharmacokinetic study of CT-011, a humanized antibody interacting with PD-1, in patients with advanced hematologic malignancies. Clin Cancer Res 14:3044-3051.
31. Uno T, et al. (2006) Eradication of established tumors in mice by a combination antibody-based therapy. Nat Med 12:693-698. (Pubitemid 43865240)
32. Takeda K, Okumura K, Smyth MJ (2007) Combination antibody-based cancer immunotherapy. Cancer Sci 98:1297-1302. (Pubitemid 47241748)
33. Sznol M (2008) Phase I study of BMS-663513, a fully human anti-CD137 agonist monoclonal antibody, in patients with advanced cancer. ASCO Annual Meeting Proceedings. J Clin Oncol 26(15S Suppl):3007.
34. Kim PS, et al. (2008) Antibody association with HER-2/neu-targeted vaccine enhances CD8 T cell responses in mice through Fc-mediated activation of DCs. J Clin Invest 118: 1700-1711. (Pubitemid 351632374)